Citadel Advisors’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Citadel Advisors’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,670	Closed	-$31.3K	–	15496
2024 Q2	$31.3K	Buy	+24,670	New	+$32.6K	﹤0.01%	12226
2024 Q1	–	Sell	-54,018	Closed	-$85.9K	–	15619
2023 Q4	$85.9K	Buy	54,018 +39,881	+282%	+$50.8K	﹤0.01%	11125
2023 Q3	$20.1K	Sell	14,137 -2,842	-17%	-$4.37K	﹤0.01%	12627
2023 Q2	$27K	Sell	16,979 -1,522	-8%	-$1.94K	﹤0.01%	12461
2023 Q1	$15.6K	Buy	+18,501	New	+$26.3K	﹤0.01%	13248

Other funds holding CYTH

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FFVM

Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's CYTH Position: Q3 2024 in Review

Citadel Advisors sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q3 2024, closing a stake of 24,670 shares — an estimated $31.3K sold.

Citadel Advisors first reported a position in CYTH in Q1 2023 and held it in 5 quarters. The position peaked at $85.9K in Q4 2023. 19 funds tracked by Wall St. Rank hold CYTH as of Q3 2024.

Citadel Advisors reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Citadel Advisors sold 24,670 Cyclo Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $31.3K.
Citadel Advisors first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
Citadel Advisors's Cyclo Therapeutics, Inc. Common Stock position peaked at $85.9K in Q4 2023.
19 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.